Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma

Table 2 Clinical characteristics of patients who survived longer than two years after sorafenib treatment

Child-Pugh class (score)	AFP ^a (ng/mL)	Cause of failure of sorafenib treatment	Subsequent therapy			Survival after sorafenib treatment (months), Status at analysis
Child-Pugh class (score)	AFP ^a (ng/mL)	Cause of failure of sorafenib treatment	Therapies targeting intra-hepatic lesion	Response^b to hepatic arterial infusion chemotehrapy	Systemic therapy
A (6)	15	adverse effect	hepatic arterial infusion chemotherapy, radio frequent ablation	Partial response	Radiotherapy (for bone metastases), cytotoxic chemotherapy, immunotherapy	28.4 dead
A (5)	16	adverse effect	hepatic arterial infusion chemotherapy	Partial response	cytotoxic chemotherapy, sorafenib re-administration	68.5 alive
A (5)	17688	tumor progression	radio frequent ablation	-	Radiotherpay (for brain metastases), immunotherapy	46.8 dead
B (9)	11	adverse effect	hepatic arterial infusion chemotherapy, transarterial chemoembolization, radio frequent ablation	Partial response	cytotoxic chemotherapy	38.6 dead
A (5)	964	tumor progression	hepatic arterial infusion chemotherapy, transarterial chemoembolization radio frequent ablation, radiotherapy	Stable disease	-	40.0 alive

ISSN: 1471-2407